Therapy of chronic hepatitis C with simeprevir

Czech version

Authors: P. Urbánek
Authors‘ workplace: Interní klinika 1. LF UK a ÚVN Praha
Published in: Gastroent Hepatol 2015; 69(2): 103-108
Category: Hepatology: Review article
doi: https://doi.org/10.14735/amgh2015103

Overview

This review presents all essential information on simeprevir and its use in the therapy of chronic hepatitis C. The review is focused on the curent role of simeprevir in IFN‑based regimens as well as its role in IFN‑free regimens.

Key words:
viral hepatitis C – simeprevir – pegylated interferon

The author declares he has no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Sources

1. Jacobson IM, Dore GJ, Foster GR et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment‑ naive patients with chronic hepatitis C virus genotype 1 infection (QUEST‑1): a phase 3, randomised, double‑blind, placebo‑ controlled trial. Lancet 2014; 384(9941): 403– 413. doi: 10.1016/ S0140‑ 6736(14)60494‑ 3.

2. Manns M, Marcellin P, Poordad F et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment‑ naive patients with chronic hepatitis C virus genotype 1 infection (QUEST‑2): a randomised, double‑blind, placebo‑ controlled phase 3 trial. Lancet 2014; 384(9941): 414– 426. doi: 10.1016/ S0140‑ 6736(14)60538‑ 9.

3. Forns X, Lawitz E, Zeuzem S et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146(7): 1669– 1679. doi: 10.1053/ j.gastro.2014.02.051.

4. Scott J, Gilles L, Fu M et al. Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‑1, QUEST‑2 and PROMISE studies. J Viral Hepat 2014. doi: 10.1111/ jvh.12365.

5. Urbánek P, Husa P, Šperl J et al. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C (HCV). Gastroent Hepatol 2014; 68(6): 499– 512.